Literature DB >> 19557833

The generation of stable, high MAb expressing CHO cell lines based on the artificial chromosome expression (ACE) technology.

Malcolm L Kennard1, Danika L Goosney, Diane Monteith, Lin Zhang, Mark Moffat, David Fischer, John Mott.   

Abstract

The manufacture of recombinant proteins at industrially relevant levels requires technologies that can engineer stable, high expressing cell lines rapidly, reproducibly and with relative ease. Commonly used methods incorporate transfection of mammalian cell lines with plasmid DNA containing the gene of interest. Identifying stable high expressing transfectants is normally laborious and time consuming. To improve this process, the ACE System has been developed based on pre-engineered artificial chromosomes with multiple recombination acceptor sites. This system allows for the targeted transfection of single or multiple genes and eliminates the need for random integration into native host chromosomes. To illustrate the utility of the ACE System in generating stable, high expressing cell lines, CHO based candidate cell lines were generated to express a human monoclonal IgG1 antibody. Candidate cell lines were generated in under 6 months and expressed over 1 g/L and with specific productivities of up to 45 pg/cell/day under non-fed, non-optimized shake flask conditions. These candidate cell lines were shown to have stable expression of the monoclonal antibody for up to 70 days of continuous culture. The results of this study demonstrate that clonal, stable monoclonal antibody expressing CHO based cell lines can be generated by the ACE System rapidly and perform competitively with those cell lines generated by existing technologies. The ACE System, therefore, provides an attractive and practical alternative to conventional methods of cell line generation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19557833     DOI: 10.1002/bit.22406

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  8 in total

Review 1.  De novo formed satellite DNA-based mammalian artificial chromosomes and their possible applications.

Authors:  Robert L Katona
Journal:  Chromosome Res       Date:  2015-02       Impact factor: 5.239

2.  A method for producing transgenic cells using a multi-integrase system on a human artificial chromosome vector.

Authors:  Shigeyuki Yamaguchi; Yasuhiro Kazuki; Yuji Nakayama; Eiji Nanba; Mitsuo Oshimura; Tetsuya Ohbayashi
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

3.  Novel method to load multiple genes onto a mammalian artificial chromosome.

Authors:  Anna Tóth; Katalin Fodor; Tünde Praznovszky; Vilmos Tubak; Andor Udvardy; Gyula Hadlaczky; Robert L Katona
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 4.  A pathway from chromosome transfer to engineering resulting in human and mouse artificial chromosomes for a variety of applications to bio-medical challenges.

Authors:  Mitsuo Oshimura; Narumi Uno; Yasuhiro Kazuki; Motonobu Katoh; Toshiaki Inoue
Journal:  Chromosome Res       Date:  2015-02       Impact factor: 5.239

5.  Development of a synthetic gene network to modulate gene expression by mechanical forces.

Authors:  Zoltán Kis; Tania Rodin; Asma Zafar; Zhangxing Lai; Grace Freke; Oliver Fleck; Armando Del Rio Hernandez; Leila Towhidi; Ryan M Pedrigi; Takayuki Homma; Rob Krams
Journal:  Sci Rep       Date:  2016-07-12       Impact factor: 4.379

Review 6.  Strategies and Considerations for Improving Recombinant Antibody Production and Quality in Chinese Hamster Ovary Cells.

Authors:  Jun-He Zhang; Lin-Lin Shan; Fan Liang; Chen-Yang Du; Jing-Jing Li
Journal:  Front Bioeng Biotechnol       Date:  2022-03-04

7.  Advances in Mammalian cell line development technologies for recombinant protein production.

Authors:  Tingfeng Lai; Yuansheng Yang; Say Kong Ng
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-26

Review 8.  Utilization of Site-Specific Recombination in Biopharmaceutical Production.

Authors:  Maryam Ahmadi; Narges Damavandi; Mohammad Reza Akbari Eidgahi; Fatemeh Davami
Journal:  Iran Biomed J       Date:  2015-11-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.